196 related articles for article (PubMed ID: 30945556)
1. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Damalanka VC; Janetka JW
Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
Han Z; Harris PK; Jones DE; Chugani R; Kim T; Agarwal M; Shen W; Wildman SA; Janetka JW
ACS Med Chem Lett; 2014 Nov; 5(11):1219-24. PubMed ID: 25408834
[TBL] [Abstract][Full Text] [Related]
5. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
Gray K; Elghadban S; Thongyoo P; Owen KA; Szabo R; Bugge TH; Tate EW; Leatherbarrow RJ; Ellis V
Thromb Haemost; 2014 Aug; 112(2):402-11. PubMed ID: 24696092
[TBL] [Abstract][Full Text] [Related]
6. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
7. Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.
Damalanka VC; Wildman SA; Janetka JW
Medchemcomm; 2019 Sep; 10(9):1646-1655. PubMed ID: 31803403
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Mukai S; Yamasaki K; Fujii M; Nagai T; Terada N; Kataoka H; Kamoto T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290402
[TBL] [Abstract][Full Text] [Related]
9. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Han Z; Harris PK; Karmakar P; Kim T; Owusu BY; Wildman SA; Klampfer L; Janetka JW
ChemMedChem; 2016 Mar; 11(6):585-99. PubMed ID: 26889658
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
Hashimoto T; Kato M; Shimomura T; Kitamura N
FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of bisbenzamidines as inhibitors for matriptase-2.
Beckmann AM; Gilberg E; Gattner S; Huang TL; Vanden Eynde JJ; Mayence A; Bajorath J; Stirnberg M; Gütschow M
Bioorg Med Chem Lett; 2016 Aug; 26(15):3741-5. PubMed ID: 27287367
[TBL] [Abstract][Full Text] [Related]
12. Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
St-Georges C; Désilets A; Béliveau F; Ghinet M; Dion SP; Colombo É; Boudreault PL; Najmanovich RJ; Leduc R; Marsault É
Eur J Med Chem; 2017 Mar; 129():110-123. PubMed ID: 28219045
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Development of TMPRSS6 Inhibitors Modulating Hepcidin Levels in Human Hepatocytes.
Béliveau F; Tarkar A; Dion SP; Désilets A; Ghinet MG; Boudreault PL; St-Georges C; Marsault É; Paone D; Collins J; Macphee CH; Campobasso N; Groy A; Cottom J; Ouellette M; Pope AJ; Leduc R
Cell Chem Biol; 2019 Nov; 26(11):1559-1572.e9. PubMed ID: 31543462
[TBL] [Abstract][Full Text] [Related]
14. Roles and regulation of membrane-associated serine proteases.
Qiu D; Owen K; Gray K; Bass R; Ellis V
Biochem Soc Trans; 2007 Jun; 35(Pt 3):583-7. PubMed ID: 17511657
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances of Hepsin-Targeted Inhibitors.
Kwon H; Han J; Lee KY; Son SH; Byun Y
Curr Med Chem; 2017; 24(21):2294-2311. PubMed ID: 28245763
[TBL] [Abstract][Full Text] [Related]
16. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
17. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Enyedy IJ; Lee SL; Kuo AH; Dickson RB; Lin CY; Wang S
J Med Chem; 2001 Apr; 44(9):1349-55. PubMed ID: 11311057
[TBL] [Abstract][Full Text] [Related]
18. The role of type II transmembrane serine protease-mediated signaling in cancer.
Tanabe LM; List K
FEBS J; 2017 May; 284(10):1421-1436. PubMed ID: 27870503
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Kwon H; Ha H; Jeon H; Jang J; Son SH; Lee K; Park SK; Byun Y
Bioorg Chem; 2021 Feb; 107():104521. PubMed ID: 33334587
[TBL] [Abstract][Full Text] [Related]
20. Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
Zoratti GL; Tanabe LM; Hyland TE; Duhaime MJ; Colombo É; Leduc R; Marsault E; Johnson MD; Lin CY; Boerner J; Lang JE; List K
Oncotarget; 2016 Sep; 7(36):58162-58173. PubMed ID: 27528224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
